Khaled Elsayad, Emmanuella Guenova, Beatrice Fournier, Carolina Fernandes, Enrico Clementel, Evangelia Papadavid, Marie Beylot Barry, Felix Pavlotsky, Lena Specht, Mario Levis, Stephen Morris, Belinda Campbell, Jan P Nicolay, Richard Cowan, Dora Correia, Chalid Assaf, Pablo L Ortiz-Romero, Vassilis Kouloulias, Adele de Masson, Stephane Dalle, Pierre Clavère, Max Schlaak, Nina Booken, Marion Wobser, Christina Mitteldorf, Barzilai Aviv, Virgínia Mareco, Fernando Gallardo, Reinhard Dummer, Markus Gross, Felix Ehret, Andrea Lancia, Bartłomiej Tomasik, Lorna Hawley, Vincent Rermouchamps, Mona Abdel-Halim Ibrahim, Ahmed Gawish, Mohamed Abouegylah, Martin Stuschke, Adinda Baten, Hans Theodor Eich
{"title":"Real-world Pattern-of-Care Analysis of Cutaneous Lymphomas Radiotherapy Among EORTC Members.","authors":"Khaled Elsayad, Emmanuella Guenova, Beatrice Fournier, Carolina Fernandes, Enrico Clementel, Evangelia Papadavid, Marie Beylot Barry, Felix Pavlotsky, Lena Specht, Mario Levis, Stephen Morris, Belinda Campbell, Jan P Nicolay, Richard Cowan, Dora Correia, Chalid Assaf, Pablo L Ortiz-Romero, Vassilis Kouloulias, Adele de Masson, Stephane Dalle, Pierre Clavère, Max Schlaak, Nina Booken, Marion Wobser, Christina Mitteldorf, Barzilai Aviv, Virgínia Mareco, Fernando Gallardo, Reinhard Dummer, Markus Gross, Felix Ehret, Andrea Lancia, Bartłomiej Tomasik, Lorna Hawley, Vincent Rermouchamps, Mona Abdel-Halim Ibrahim, Ahmed Gawish, Mohamed Abouegylah, Martin Stuschke, Adinda Baten, Hans Theodor Eich","doi":"10.1016/j.ijrobp.2024.11.011","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>We aim to determine the current treatment patterns and recommendations among physicians for cutaneous lymphomas and to identify the types of skin lymphomas for which existing radiation regimens need improvement.</p><p><strong>Materials/methods: </strong>A questionnaire from the European Organisation for Research and Treatment of Cancer (EORTC) was distributed to all members of the Cutaneous Lymphoma Tumour Group and radiation oncology scintific council. This online survey included 13 questions regarding treatment practices for patients with cutaneous lymphoma. The survey was conducted from August 21 to December 18, 2023. Frequency distributions and subgroup comparisons were calculated and analyzed.</p><p><strong>Results: </strong>We collected 51 completed questionnaires from investigators from 19 countries specializing in cutaneous lymphoma treatment. Radiation doses varied significantly (range, 4-60 Gy). Based on the histologic entity, up to one-third of the investigators delivered hypofractionated regimens (range, 14% - 35%). Reduced-dose radiotherapy was considered by 27% to 63% of investigators. Meanwhile, 18 (35%) investigators considered adapting the radiation dose to the response to immunochemotherapy when treating primary cutaneous diffuse large B-cell lymphomal-leg type. Regarding total skin electron beam therapy, 91% of centres delivered reduced-dose regimens, and 18% of investigators applied ultra-hypofractionated protocols.</p><p><strong>Conclusion: </strong>Radiotherapy of cutaneous lymphoma patients is highly heterogeneous among EORTC centres. Development of evidence-based recommendations for radiotherapy dose, fractionation, and technique for cutaneous lymphomas is required for optimization and standardization of treatment.</p>","PeriodicalId":14215,"journal":{"name":"International Journal of Radiation Oncology Biology Physics","volume":" ","pages":""},"PeriodicalIF":6.4000,"publicationDate":"2024-11-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Radiation Oncology Biology Physics","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.ijrobp.2024.11.011","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Purpose: We aim to determine the current treatment patterns and recommendations among physicians for cutaneous lymphomas and to identify the types of skin lymphomas for which existing radiation regimens need improvement.
Materials/methods: A questionnaire from the European Organisation for Research and Treatment of Cancer (EORTC) was distributed to all members of the Cutaneous Lymphoma Tumour Group and radiation oncology scintific council. This online survey included 13 questions regarding treatment practices for patients with cutaneous lymphoma. The survey was conducted from August 21 to December 18, 2023. Frequency distributions and subgroup comparisons were calculated and analyzed.
Results: We collected 51 completed questionnaires from investigators from 19 countries specializing in cutaneous lymphoma treatment. Radiation doses varied significantly (range, 4-60 Gy). Based on the histologic entity, up to one-third of the investigators delivered hypofractionated regimens (range, 14% - 35%). Reduced-dose radiotherapy was considered by 27% to 63% of investigators. Meanwhile, 18 (35%) investigators considered adapting the radiation dose to the response to immunochemotherapy when treating primary cutaneous diffuse large B-cell lymphomal-leg type. Regarding total skin electron beam therapy, 91% of centres delivered reduced-dose regimens, and 18% of investigators applied ultra-hypofractionated protocols.
Conclusion: Radiotherapy of cutaneous lymphoma patients is highly heterogeneous among EORTC centres. Development of evidence-based recommendations for radiotherapy dose, fractionation, and technique for cutaneous lymphomas is required for optimization and standardization of treatment.
期刊介绍:
International Journal of Radiation Oncology • Biology • Physics (IJROBP), known in the field as the Red Journal, publishes original laboratory and clinical investigations related to radiation oncology, radiation biology, medical physics, and both education and health policy as it relates to the field.
This journal has a particular interest in original contributions of the following types: prospective clinical trials, outcomes research, and large database interrogation. In addition, it seeks reports of high-impact innovations in single or combined modality treatment, tumor sensitization, normal tissue protection (including both precision avoidance and pharmacologic means), brachytherapy, particle irradiation, and cancer imaging. Technical advances related to dosimetry and conformal radiation treatment planning are of interest, as are basic science studies investigating tumor physiology and the molecular biology underlying cancer and normal tissue radiation response.